Evernorth Announces Appointment of New Board Members and Senior Executives Ahead of Anticipated Public Listing Accessibility Statement Skip NavigationBoard to add four directors with deep public-company, regulatory and digital asset experienceCompany also names Chief Risk Officer and Chief Communications OfficerSAN FRANCISCO, May 5, 2026 /PRNewswire/ -- Evernorth Holdings, Inc. ("Evernorth"), a newly formed Nevada corporation that will enable adoption of XRP on an institutional scale, today announced the ap ...

Traction Engages Special Projects Inc. to Advance Aurora Toward Target RefinementCALGARY, Alberta, May 05, 2026 (GLOBE NEWSWIRE) -- Traction Uranium Corp. (CSE: TRAC) (OTC: TRCTF) (FRA: Z1K) (the “Company” or “Traction”) is pleased to announce that Special Projects Inc. (“SPI”) has been engaged to complete an airborne radiometric survey at the Aurora Uranium Project (“Aurora” or the “Project”), located in Saskatchewan’s Athabasca Basin region. The survey will be completed under the direction of Cosa Resourc ...

公司活动与信息 - Septerna公司首席执行官兼联合创始人Jeffrey Finer博士将于2026年5月12日太平洋时间下午5点，在拉斯维加斯举行的美国银行证券医疗保健会议上发表演讲 [1] - 演讲将通过公司官网投资者关系栏目进行网络直播，直播内容将在演讲结束后存档至少30天 [2] 公司业务与平台 - Septerna是一家临床阶段的生物技术公司，拥有世界级的GPCR专家和药物开发团队，致力于为存在显著未满足需求的患者释放GPCR疗法的全部潜力 [3] - 公司的专有技术平台是Native Complex Platform，该平台旨在为GPCR药物发现提供新方法，并已推动开发出多样化的新型口服小分子候选药物管线 [3] 研发管线与合作 - 公司正在独立或与合作伙伴共同推进在内分泌学、免疫学与炎症、代谢疾病及其他治疗领域的研发项目 [3]

Frontier Airlines Reports First Quarter 2026 Financial Results Accessibility Statement Skip Navigation DENVER, May 5, 2026 /PRNewswire/ -- Frontier Group Holdings, Inc. (Nasdaq: ULCC), parent company of Frontier Airlines, Inc., today reported financial results for the first quarter of 2026 and issued guidance for the second quarter 2026 and select guidance for full-year 2026. First Quarter 2026 Select Financial Highlights The following is a summary of first quarter and select financial results, including bo ...

MARLBOROUGH, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- - IPG Photonics Corporation (NASDAQ: IPGP), the global leader in fiber laser technology, today announced that it has entered into an agreement with TRUMPF Laser- und Systemtechnik SE to resolve and dismiss all patent litigation worldwide between the parties. ContactEugene FedotoffSenior Director, Investor Relations IPG Photonics Corporation 508-597-4713efedotoff@ipgphotonics.com About IPG Photonics CorporationIPG Photonics Corporation is the leader in hig ...

MINNEAPOLIS, May 05, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces it will report its financial results for the first quarter ended March 31, 2026 premarket on Tuesday, May 12, 2026. The Company will subsequently host a conference call and webcast at 9:00 AM ET on May 12, 2026 to discuss its financial results and provide an update on the Company's performance. To access the live webca ...

Strong Start to the Year on Growing Demand and Continued Focus on Execution of Strategic Initiatives Managing Costs and Mitigating Tariff Impact on Gross Margin MARLBOROUGH, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- IPG Photonics Corporation (NASDAQ: IPGP) today reported financial results for the first quarter ended March 31, 2026. Three Months Ended March 31,(In millions, except per share data and percentages) 2026 2025 ChangeRevenue $265.5 <td style="max-width:1%; width:1%; ...

公司动态 - Filana Therapeutics公司在西班牙马德里举行的第十八届埃拉特新型抗癫痫药物与设备会议上，介绍了其候选药物simufilam用于治疗结节性硬化症相关癫痫的生物学原理 [1] - 公司首席执行官Rick Barry表示，公司正专注于解决美国食品药品监督管理局的临床搁置问题所需的工作，并将在获得进展后提供更新 [2] - 公司正在处理美国食品药品监督管理局在2025年12月的临床搁置信中提出的信息请求，包括提交额外的临床前数据和修改试验方案设计 公司计划在完成这些工作后向美国食品药品监督管理局提交答复，并预计在未来几个月内提供项目更新 [4] 产品与研发 - 公司的核心研发项目是评估simufilam用于治疗结节性硬化症相关癫痫 [1] - Simufilam是一种研究性疗法，旨在通过调节细丝蛋白A来治疗中枢神经系统疾病，如结节性硬化症相关癫痫，以及其他与细丝蛋白A失调或过度表达相关的疾病 [5] 市场与疾病背景 - 结节性硬化症是一种由TSC1或TSC2基因突变引起的罕见遗传性疾病，会影响雷帕霉素机制靶点通路，并可能导致多个器官生长肿瘤 [3] - 癫痫是影响结节性硬化症患者最常见的健康问题，**80%至90%**的结节性硬化症患者会经历癫痫发作 [3] - 在美国，结节性硬化症相关癫痫影响约**45,000人** 大多数患者在出生后第一年内开始出现癫痫发作 [3] - 即使有多种获批疗法，仍有**超过60%**的结节性硬化症患者对抗癫痫治疗无效（耐药） [3]

PROTOTYPE FLIGHT CAMPAIGN 59 TOTAL FLIGHTS 2h 27min TOTAL FLIGHT TIME 1 2 3 4 5 6 8 9 10 11 13 151617 181920 22 24 26 28 29 313233 35 3637 39 41 42 444546 474849 5152 54 56575859 0:00 0:21 0:43 1:04 1:26 1:48 2:09 2:31 0 1 0 2 0 3 0 4 0 5 0 6 0 7 0 19-Dec-25 03-Jan-26 18-Jan-26 02-Feb-26 17-Feb-26 04-Mar-26 19-Mar-26 03-Apr-26 18-Apr-26 Total flights, left axis Total time (hour:minutes), right axis Christmas / New Year's break Software upload & tests for envelope expansion Denotes two flights / day 1 Q 2 0 ...

Forward-Looking Statements and Non-GAAP Financial Measures Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding anticipated adjusted and organic revenue growth, adjusted earnings per share, adjusted operating margin, free cash flow, free cash flow conversion, adjusted annual effective income tax rate, capital expenditures, and other statements regarding our future financial ...